Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia
Authors' conclusion
SGLT2i use among older adults with T2DM in British Columbia increased steadily from 2016 to 2022, followed by a spike in 2023, aligned with the expansion in publicly funded drug coverage. By the end of 2023, around one in five used SGLT2is, regardless of cardiorenal disease status.
Study context
- Population
- All individuals aged ≥75 years with T2D in British Columbia, Canada, January 1, 2016 to December 31, 2023
- Outcome
- Prevalence and incidence of SGLT2i use, characteristics of incident users, and discontinuation
Methodological detailsadministrative healthcare databases, population-based
- Administrative healthcare databases
- Population-based
Main finding
As reported in the abstract
Prevalence of SGLT2i use
- Prevalence, first half of 2016
- 2.0%
- Prevalence, second half of 2022
- 14%
- Prevalence, second half of 2023
- 21%
- Prevalence in 2023, with vs without cardiorenal disease
- 20% vs. 22%
- SGLT2i initiation, 2016 to 2022
- 1.3 to 2.8 per 1000 individuals
- SGLT2i initiation, January 2023 (spike, then stabilised)
- 5.4 per 1000 individuals
Observational data: associations, not effects.
Further findings
Characteristics of SGLT2i initiators 2021–2023
- SGLT2i initiators
- 14 320
- Had cardiorenal disease
- 62%
- Concomitant metformin
- 68%
- Concomitant sulfonylureas
- 39%
- Concomitant insulins
- 19%
- Started by a general practitioner
- 62%
Discontinuation within a year
- Discontinued treatment within a year
- 17%
Original publication
Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia. Diabetes Obes Metab. Published 12 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →